4.Predictive value of CHADS2 score for cardiovascular events in patients with acute coronary syndrome and documented coronary artery disease.
In Sook KANG ; Wook Bum PYUN ; Gil Ja SHIN
The Korean Journal of Internal Medicine 2016;31(1):73-81
BACKGROUND/AIMS: The CHADS2 score, used to predict the risk of ischemic stroke in atrial fibrillation (AF) patients, has been reported recently to predict ischemic stroke in patients with coronary heart disease, regardless of the presence of AF. However, little data are available regarding the relationship between the CHADS2 score and cardiovascular outcomes. METHODS: This was a retrospective study on 104 patients admitted for acute coronary syndrome (ACS) who underwent coronary angiography, carotid ultrasound, and transthoracic echocardiography. RESULTS: The mean age of the subjects was 60.1 +/- 12.6 years. The CHADS2 score was as follows: 0 in 46 patients (44.2%), 1 in 31 (29.8%), 2 in 18 (17.3%), and > or = 3 in 9 patients (8.7%). The left atrial volume index (LAVi) showed a positive correlation with the CHADS2 score (20.8 +/- 5.9 for 0; 23.2 +/- 6.7 for 1; 26.6 +/- 10.8 for 2; and 30.3 +/- 8.3 mL/m2 for > or =3; p = 0.001). The average carotid total plaque area was significantly increased with CHADS2 scores > or = 2 (4.97 +/- 7.17 mm2 vs. 15.52 +/- 14.61 mm2; p = 0.002). Eight patients experienced cardiovascular or cerebrovascular (CCV) events during a mean evaluation period of 662 days. A CHADS2 score > or = 3 was related to an increase in the risk of CCV events (hazard ratio, 14.31; 95% confidence interval, 3.53 to 58.06). Furthermore, LAVi and the severity of coronary artery obstructive disease were also associated with an increased risk of CCV events. CONCLUSIONS: The CHADS2 score may be a useful prognostic tool for predicting CCV events in ACS patients with documented coronary artery disease.
Acute Coronary Syndrome/complications/*diagnostic imaging
;
Aged
;
Carotid Arteries/*diagnostic imaging
;
Carotid Artery Diseases/complications/*diagnostic imaging
;
Cerebrovascular Disorders/diagnosis/*etiology
;
*Coronary Angiography
;
Coronary Artery Disease/complications/*diagnostic imaging
;
*Decision Support Techniques
;
*Echocardiography
;
Female
;
Humans
;
Male
;
Middle Aged
;
Plaque, Atherosclerotic
;
Predictive Value of Tests
;
Prognosis
;
Republic of Korea
;
Retrospective Studies
;
Risk Assessment
;
Risk Factors
;
Severity of Illness Index
;
Time Factors
5.Plasma Levels of Soluble CD146 Reflect the Severity of Pulmonary Congestion Better Than Brain Natriuretic Peptide in Acute Coronary Syndrome.
Petr KUBENA ; Mattia ARRIGO ; Jiri PARENICA ; Etienne GAYAT ; Malha SADOUNE ; Eva GANOVSKA ; Marie PAVLUSOVA ; Simona LITTNEROVA ; Jindrich SPINAR ; Alexandre MEBAZAA
Annals of Laboratory Medicine 2016;36(4):300-305
BACKGROUND: Acute heart failure negatively affects short-term outcomes of patients with acute coronary syndrome (ACS). Therefore, reliable and non-invasive assessment of pulmonary congestion is needed to select patients requiring more intensive monitoring and therapy. Since plasma levels of natriuretic peptides are influenced by myocardial ischemia, they might not reliably reflect congestion in the context of ACS. The novel endothelial biomarker, soluble CD146 (sCD146), presents discriminative power for detecting the cardiac origin of acute dyspnea similar to that of natriuretic peptides and is associated with systemic congestion. We evaluated the performance of sCD146 for the assessment of pulmonary congestion in the early phase of ACS. METHODS: One thousand twenty-one consecutive patients with ACS were prospectively enrolled. Plasma levels of sCD146, brain natriuretic peptide (BNP), and high-sensitive troponin T were measured within 24 hr after the onset of chest pain. Pulmonary congestion on chest radiography was determined and classified in three groups according to the degree of congestion. RESULTS: Nine hundred twenty-seven patients with ACS were analyzed. Ninety-two (10%) patients showed signs of pulmonary edema on chest radiography. Plasma levels of sCD146 reflected the radiological severity of pulmonary congestion. Higher plasma levels of sCD146 were associated with the worse degree of pulmonary congestion. In contrast to BNP, sCD146 levels were not affected by the level of troponin T. CONCLUSIONS: The novel endothelial biomarker, sCD146, correlates with radiological severity of pulmonary congestion in the early phase of ACS and, in contrast to BNP, is not affected by the amount of myocardial cell necrosis.
Acute Coronary Syndrome/*diagnosis/diagnostic imaging
;
Aged
;
Antigens, CD146/blood
;
Biomarkers/blood
;
Chest Pain/diagnostic imaging/*pathology
;
Electrocardiography
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myocardial Infarction/diagnosis
;
Natriuretic Peptide, Brain/*blood
;
Severity of Illness Index
;
Troponin T/blood